VC: Affymax leads venture rounds with $60M



Affymax pockets $60M in fourth round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Affymax
Palo Alto, CA

$60 million
fourth round

JAFCO, Bear Stearns Health Innoventures

Much of the money will go to a Phase II clinical program for Hematide in patients with chronic kidney disease and cancer.

Ilypsa
Santa Clara, CA

$36 million
round two

US Venture Partners, Johnson & Johnson Development Corporation, and Delphi Ventures

Ilypsa will use the funds to complete preclinical and initiate clinical development of their two lead compounds ILY-101, a metal-free, polymeric phosphate binder, and ILY-105, a novel potassium-binding polymer.

Labcyte
Sunnyvale, CA

$21 million
third round

Cross Atlantic Partners

Labcyte is developing its low-volume liquid handling business, which is based on a proprietary technology for using focused acoustics to precisely transfer nanoliters of liquid.

Peptimmune
Cambridge, MA

$20.4 million
third round

New Enterprise Associates

Peptimmune's lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity.

BrainCells
San Diego

$17.7 million
round one

Technology Partners, Oxford Bioscience Partners, and Bay City Capital

The money will go to identify one or more late-stage clinical compounds currently under development for a CNS indication.

APT Pharmaceuticals
Tucson, AZ

$6 million
round one

Charter Life Sciences

The funds go to support a Phase II trial of an inhaled version of hydroxychloroquine for asthma.

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.